Analysis of I-Trace High Order Aberrations Induced by Wavefront Optimized Ablation Profiles


This work aims at the analysis of ocular aberrations induced by wave front optimized ablation profiles WFO using I-Trace aberrometer (Ray -Tracing)

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 30, 2020

Detailed Description

The iTrace (Tracey Technologies, Houston, Tx) is uniquely designed to combine Placido corneal topography with a ray tracing aberrometer to measure quality of vision in a patient. This work aims at the analysis of ocular aberrations induced by wave front optimized ablation profiles WFO using I-Trace aberrometer (Ray -Tracing)


  • Device: LASIK
    • All cases were operated upon using Wavelight Allegretto EX-500 excimer laser (Alcon Laboratories, Inc., Fort Worth, TX) with wave front optimized ablation profile WFO. The Moria II microkeratome (Moria, Anthony, France) was used in all cases.

Arms, Groups and Cohorts

  • Experimental: Laser in situ keratomileusis
    • A prospective clinical study including 20 eyes of 10 cases undergoing laser in situ keratomileusis (LASIK)

Clinical Trial Outcome Measures

Primary Measures

  • Evaluation of ocular aberrations
    • Time Frame: 3 months
    • 3. Evaluation of ocular aberrations done using iTrace Visual Functional Analyzer (ray tracing technology) to quantify changes in total higher order aberrations, coma, spherical aberrations, secondary astigmatism and trefoil after LASIK surgery
  • Visual acuity
    • Time Frame: 3 months
    • Unaided as well as best corrected visual acuity
  • Manifest refraction
    • Time Frame: 3 months
    • Manifest refraction

Participating in This Clinical Trial

Inclusion Criteria

1. Myopia up to -8.0 D and astigmatism up to -2.0D.

2. Cases above 18 years of age with a stable refraction for at least one year.

Exclusion Criteria

1. Keratoconus.

2. Patients with collagen diseases.

3. Previous LASIK or any other refractive surgery.

4. Severe dry eye syndrome.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Alexandria University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ehab Mossallam, PhD, Principal Investigator, Alexandria Faculty of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.